AAD indicates antiarrhythmic drug; AF, atrial fibrillation; AP, accessory pathway; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular tachycardia; BB, beta blocker; CCB, calcium channel blocker; CE, cost effectiveness; CVA, cerebrovascular accident; c/w, consistent with; ED, emergency department; EP, electrophysiological; HCUP, Healthcare Cost and Utilization Project; LOS, length of stay; N/A, not applicable; NS, non-significant; PPM, permanent pacemaker; PSVT, paroxysmal supraventricular tachycardia; pt, patient; QALY, quality-adjusted life year; QOL, quality of life; RF, radiofrequency; RFA, radiofrequency ablation; rx, therapy; SCD, sudden cardiac death; SF-36, Short Form (36) Heatlh Survey; w/, with; and w/o, without.
AAD indicates antiarrhythmic drug; AF, atrial fibrillation; AP, accessory pathway; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular tachycardia; BB, beta blocker; CCB, calcium channel blocker; CE, cost effectiveness; CVA, cerebrovascular accident; c/w, consistent with; ED, emergency department; EP, electrophysiological; HCUP, Healthcare Cost and Utilization Project; LOS, length of stay; N/A, not applicable; NS, non-significant; PPM, permanent pacemaker; PSVT, paroxysmal supraventricular tachycardia; pt, patient; QALY, quality-adjusted life year; QOL, quality of life; RF, radiofrequency; RFA, radiofrequency ablation; rx, therapy; SCD, sudden cardiac death; SF-36, Short Form (36) Heatlh Survey; w/, with; and w/o, without.